SpotDraft, a contract lifecycle management platform with AI-powered features, has raised $54 million in a new funding round.

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing, Biller ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

As previously reported yesterday afternoon, Canaccord upgraded Vertex Pharmaceuticals (VRTX) to Hold from Sell with a price target of $424, up ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Here’s everything you need to know about the latest Google Gemini 2.0 update, including new AI models like Flash, Pro, and ...

U.S. stocks started lower on Tuesday as investors await Fed Chair Powell's remarks about the economy, tariffs, inflation and more.

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce the appointment of experienced mining executive Sean Richardson as an In ...

Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported fourth-quarter earnings of $913 million. On a per-share basis, the Boston-based company said it had profit of $3.50.